{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:29:55Z","timestamp":1712622595782},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,8]]},"DOI":"10.7759\/cureus.57804","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T07:53:06Z","timestamp":1712562786000},"source":"Crossref","is-referenced-by-count":0,"title":["Approaches in Managing Resistant Hypertension: A Review"],"prefix":"10.7759","author":[{"given":"Sanjay","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peeyush","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajat","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrashekhar  K","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyanarayan","family":"Routray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","unstructured":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019. a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021, 398:957-80. 10.1016\/S0140-6736(21)01330-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000146","article-title":"Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension","volume":"32","author":"Anchala R","year":"2014","unstructured":"Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E, Prabhakaran D. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014, 32:1170-7. 10.1097\/HJH.0000000000000146","journal-title":"J Hypertens"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APHA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APHA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018, 71:1269-324. 10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2020.08.001","article-title":"Special article - the management of resistant hypertension: a 2020 update","volume":"63","author":"Carey RM","year":"2020","unstructured":"Carey RM. Special article - the management of resistant hypertension: a 2020 update. Prog Cardiovasc Dis. 2020, 63:662-70. 10.1016\/j.pcad.2020.08.001","journal-title":"Prog Cardiovasc Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2016.03.186","article-title":"Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement","volume":"10","author":"Bhatt H","year":"2016","unstructured":"Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016, 10:493-9. 10.1016\/j.jash.2016.03.186","journal-title":"J Am Soc Hypertens"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra A","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, et al.. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011, 57:898-902. 10.1161\/HYPERTENSIONAHA.110.168948","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13166","article-title":"A bundled quality improvement program to standardize clinical blood pressure measurement in primary care","volume":"20","author":"Boonyasai RT","year":"2018","unstructured":"Boonyasai RT, Carson KA, Marsteller JA, et al.. A bundled quality improvement program to standardize clinical blood pressure measurement in primary care. J Clin Hypertens (Greenwich). 2018, 20:324-33. 10.1111\/jch.13166","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14486","article-title":"Pseudo and resistant hypertension: a chaotic perspective","volume":"24","author":"Moreno H","year":"2022","unstructured":"Moreno H. Pseudo and resistant hypertension: a chaotic perspective. J Clin Hypertens (Greenwich). 2022, 24:698-703. 10.1111\/jch.14486","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18779","article-title":"Prevalence and risk factors for resistant hypertension: cross-sectional study from a tertiary care referral hospital in South India","volume":"13","author":"Mahapatra R","year":"2021","unstructured":"Mahapatra R, Kaliyappan A, Chinnakali P, Hanumanthappa N, Govindarajalou R, Bammigatti C. Prevalence and risk factors for resistant hypertension: cross-sectional study from a tertiary care referral hospital in South India. Cureus. 2021, 13:e18779. 10.7759\/cureus.18779","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5530\/jcdr.2016.4.1","article-title":"Magnitude of resistant hypertension and impact of aldosterone to renin ratio in resistant hypertension","volume":"7","author":"Basavanagowdappa H","year":"2016","unstructured":"Basavanagowdappa H, Basavanagowdappa N, Ravikumar YS, Kulkarni P, Devegowda D. Magnitude of resistant hypertension and impact of aldosterone to renin ratio in resistant hypertension. J Cardiovasc Disease Res. 2016, 7:133-8. 10.5530\/jcdr.2016.4.1","journal-title":"J Cardiovasc Disease Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2019.09.012","article-title":"Prevalence of hypertension among Indian adults: results from the great India blood pressure survey","volume":"71","author":"Ramakrishnan S","year":"2019","unstructured":"Ramakrishnan S, Zachariah G, Gupta K, et al.. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J. 2019, 71:309-13. 10.1016\/j.ihj.2019.09.012","journal-title":"Indian Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-022-01173-w","article-title":"The burden of resistant hypertension across the world","volume":"24","author":"Brant LC","year":"2022","unstructured":"Brant LC, Passaglia LG, Pinto-Filho MM, de Castilho FM, Ribeiro AL, Nascimento BR. The burden of resistant hypertension across the world. Curr Hypertens Rep. 2022, 24:55-66. 10.1007\/s11906-022-01173-w","journal-title":"Curr Hypertens Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002801","article-title":"Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years","volume":"16","author":"Prenissl J","year":"2019","unstructured":"Prenissl J, Manne-Goehler J, Jaacks LM, et al.. Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med. 2019, 16:e1002801. 10.1371\/journal.pmed.1002801","journal-title":"PLoS Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.08.006","article-title":"Lifestyle modification for resistant hypertension: the TRIUMPH randomized clinical trial","volume":"170","author":"Blumenthal JA","year":"2015","unstructured":"Blumenthal JA, Sherwood A, Smith PJ, et al.. Lifestyle modification for resistant hypertension: the TRIUMPH randomized clinical trial. Am Heart J. 2015, 170:986-94.e5. 10.1016\/j.ahj.2015.08.006","journal-title":"Am Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-017-0754-x","article-title":"Resistant hypertension: mechanisms and treatment","volume":"19","author":"Hwang AY","year":"2017","unstructured":"Hwang AY, Dietrich E, Pepine CJ, Smith SM. Resistant hypertension: mechanisms and treatment. Curr Hypertens Rep. 2017, 19:56. 10.1007\/s11906-017-0754-x","journal-title":"Curr Hypertens Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-018-0117-3","article-title":"Emerging trends in hypertension epidemiology in India","volume":"33","author":"Gupta R","year":"2019","unstructured":"Gupta R, Gaur K, S Ram CV. Emerging trends in hypertension epidemiology in India. J Hum Hypertens. 2019, 33:575-87. 10.1038\/s41371-018-0117-3","journal-title":"J Hum Hypertens"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0578-5","article-title":"Quality of life in treatment-resistant hypertension","volume":"17","author":"Carris NW","year":"2015","unstructured":"Carris NW, Smith SM. Quality of life in treatment-resistant hypertension. Curr Hypertens Rep. 2015, 17:61. 10.1007\/s11906-015-0578-5","journal-title":"Curr Hypertens Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0541-5","article-title":"Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study","volume":"17","author":"Bhatt H","year":"2015","unstructured":"Bhatt H, Safford M, Glasser S. Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Curr Hypertens Rep. 2015, 17:541. 10.1007\/s11906-015-0541-5","journal-title":"Curr Hypertens Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0974-3","article-title":"Resistant hypertension management: comparison of the 2017 American and 2018 European high blood pressure guidelines","volume":"21","author":"Grassi G","year":"2019","unstructured":"Grassi G, Calhoun DA, Mancia G, Carey RM. Resistant hypertension management: comparison of the 2017 American and 2018 European high blood pressure guidelines. Curr Hypertens Rep. 2019, 21:67. 10.1007\/s11906-019-0974-3","journal-title":"Curr Hypertens Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia G","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al.. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023, 41:1874-2071. 10.1097\/HJH.0000000000003480","journal-title":"J Hypertens"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051455","article-title":"Rethinking resistant hypertension","volume":"11","author":"Bourque G","year":"2022","unstructured":"Bourque G, Hiremath S. Rethinking resistant hypertension. J Clin Med. 2022, 11:10.3390\/jcm11051455","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.6.9811054","article-title":"Sleep-related breathing disorder is an independent risk factor for systemic hypertension","volume":"160","author":"Grote L","year":"1999","unstructured":"Grote L, Ploch T, Heitmann J, Knaack L, Penzel T, Peter JH. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med. 1999, 160:1875-82. 10.1164\/ajrccm.160.6.9811054","journal-title":"Am J Respir Crit Care Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-014-0005-2","article-title":"Resistant hypertension caused by stenosis of the aorta in elderly women: three case reports","volume":"20","author":"Kim HD","year":"2014","unstructured":"Kim HD, Kim MN, Kim SA, et al.. Resistant hypertension caused by stenosis of the aorta in elderly women: three case reports. Clin Hypertens. 2014, 20:5. 10.1186\/s40885-014-0005-2","journal-title":"Clin Hypertens"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-02760-x","article-title":"Quantifying population level hypertension care cascades in India: a cross-sectional analysis of risk factors and disease linkages","volume":"22","author":"Kothavale A","year":"2022","unstructured":"Kothavale A, Puri P, Sangani PG. Quantifying population level hypertension care cascades in India: a cross-sectional analysis of risk factors and disease linkages. BMC Geriatr. 2022, 22:98. 10.1186\/s12877-022-02760-x","journal-title":"BMC Geriatr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpw065","article-title":"A tale of 3 trials: ACCORD, SPRINT, and SPS3. What happened?","volume":"29","author":"Krakoff LR","year":"2016","unstructured":"Krakoff LR. A tale of 3 trials: ACCORD, SPRINT, and SPS3. What happened?. Am J Hypertens. 2016, 29:1020-3. 10.1093\/ajh\/hpw065","journal-title":"Am J Hypertens"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams B","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al.. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015, 386:2059-68. 10.1016\/S0140-6736(15)00257-3","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa100","article-title":"SGLT2 inhibitors in resistant hypertension: a sweet solution","volume":"33","author":"Tran KC","year":"2020","unstructured":"Tran KC, Hiremath S. SGLT2 inhibitors in resistant hypertension: a sweet solution. Am J Hypertens. 2020, 33:1071-4. 10.1093\/ajh\/hpaa100","journal-title":"Am J Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye N","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, et al.. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021, 143:1735-49. 10.1161\/CIRCULATIONAHA.120.048740","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018827","article-title":"Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension","volume":"9","author":"Tsujimoto T","year":"2020","unstructured":"Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020, 9:e018827. 10.1161\/JAHA.120.018827","journal-title":"J Am Heart Assoc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment)","volume":"71","author":"Krieger EM","year":"2018","unstructured":"Krieger EM, Drager LF, Giorgi DM, et al.. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018, 71:681-90. 10.1161\/HYPERTENSIONAHA.117.10662","journal-title":"Hypertension"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol P","year":"2018","unstructured":"Rossignol P, Claggett BL, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S. Spironolactone and resistant hypertension in heart failure with preserved ejection fraction. Am J Hypertens. 2018, 31:407-14. 10.1093\/ajh\/hpx210","journal-title":"Am J Hypertens"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund CS","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013, 31:2094-102. 10.1097\/HJH.0b013e3283638b1a","journal-title":"J Hypertens"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2012.105","article-title":"Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial","volume":"158","author":"Vaclavik J","year":"2014","unstructured":"Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158:384-90. 10.5507\/bp.2012.105","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk J","year":"2014","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Jarkovsk\u00fd J, Koci\u00e1nov\u00e1 E, T\u00e1borsk\u00fd M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore). 2014, 93:e162. 10.1097\/MD.0000000000000162","journal-title":"Medicine (Baltimore)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza F","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010, 55:147-52. 10.1161\/HYPERTENSIONAHA.109.140988","journal-title":"Hypertension"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman N","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahl\u00f6f B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007, 49:839-45. 10.1161\/01.HYP.0000259805.18468.8c","journal-title":"Hypertension"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk J","year":"2011","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Plachy M, et al.. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011, 57:1069-75. 10.1161\/HYPERTENSIONAHA.111.169961","journal-title":"Hypertension"},{"key":"ref39","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi R","year":"2011","unstructured":"Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl. 2011, 22:75-8.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00387.x","article-title":"Drug therapy for resistant hypertension: simplifying the approach","volume":"13","author":"Mann SJ","year":"2011","unstructured":"Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich). 2011, 13:120-30. 10.1111\/j.1751-7176.2010.00387.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/08037050902843726","article-title":"Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension","volume":"18","author":"Ceral J","year":"2009","unstructured":"Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009, 18:74-7. 10.1080\/08037050902843726","journal-title":"Blood Press"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000051","article-title":"Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension","volume":"32","author":"Smith SM","year":"2014","unstructured":"Smith SM, Gong Y, Handberg E, et al.. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014, 32:635-43. 10.1097\/HJH.0000000000000051","journal-title":"J Hypertens"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_84","article-title":"Hypertension in chronic kidney disease","volume":"956","author":"Hamrahian SM","year":"2017","unstructured":"Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017, 956:307-25. 10.1007\/5584_2016_84","journal-title":"Adv Exp Med Biol"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1007\/s40119-020-00203-5","article-title":"Contemporary strategies to manage high blood pressure in patients with coexistent resistant hypertension and heart failure with reduced ejection fraction","volume":"10","author":"Lang K","year":"2021","unstructured":"Lang K, Van Iterson EH, Laffin LJ. Contemporary strategies to manage high blood pressure in patients with coexistent resistant hypertension and heart failure with reduced ejection fraction. Cardiol Ther. 2021, 10:9-25.","journal-title":"Cardiol Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s1458","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin J","year":"2008","unstructured":"Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008, 4:269-86. 10.2147\/tcrm.s1458","journal-title":"Ther Clin Risk Manag"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S368784","article-title":"A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider","volume":"16","author":"Hamrahian SM","year":"2022","unstructured":"Hamrahian SM, Maarouf OH, F\u00fcl\u00f6p T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence. 2022, 16:2749-57. 10.2147\/PPA.S368784","journal-title":"Patient Prefer Adherence"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011499.pub3","article-title":"Renal denervation for resistant hypertension","volume":"11","author":"Pisano A","year":"2021","unstructured":"Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021, 11:CD011499. 10.1002\/14651858.CD011499.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01025-9","article-title":"Novel antihypertensive agents for resistant hypertension: what does the future hold?","volume":"45","author":"Salvador VD","year":"2022","unstructured":"Salvador VD, Bakris GL. Novel antihypertensive agents for resistant hypertension: what does the future hold?. Hypertens Res. 2022, 45:1918-28. 10.1038\/s41440-022-01025-9","journal-title":"Hypertens Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/200379-approaches-in-managing-resistant-hypertension-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T07:53:09Z","timestamp":1712562789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/200379-approaches-in-managing-resistant-hypertension-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.57804","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}